ATE318912T1 - Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen - Google Patents

Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen

Info

Publication number
ATE318912T1
ATE318912T1 AT98943469T AT98943469T ATE318912T1 AT E318912 T1 ATE318912 T1 AT E318912T1 AT 98943469 T AT98943469 T AT 98943469T AT 98943469 T AT98943469 T AT 98943469T AT E318912 T1 ATE318912 T1 AT E318912T1
Authority
AT
Austria
Prior art keywords
polypeptide
transduced cells
expression
heparanase activity
polynucleotide encoding
Prior art date
Application number
AT98943469T
Other languages
English (en)
Inventor
Iris Pecker
Israel Vlodavsky
Elena Feinstein
Original Assignee
Insight Biopharmaceuticals Ltd
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25446621&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE318912(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insight Biopharmaceuticals Ltd, Hadasit Med Res Service filed Critical Insight Biopharmaceuticals Ltd
Application granted granted Critical
Publication of ATE318912T1 publication Critical patent/ATE318912T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01166—Heparanase (3.2.1.166)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, Konjac gum, Locust bean gum or Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
AT98943469T 1997-09-02 1998-08-31 Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen ATE318912T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/922,170 US5968822A (en) 1997-09-02 1997-09-02 Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US10938698A 1998-07-02 1998-07-02

Publications (1)

Publication Number Publication Date
ATE318912T1 true ATE318912T1 (de) 2006-03-15

Family

ID=25446621

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98943469T ATE318912T1 (de) 1997-09-02 1998-08-31 Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen

Country Status (12)

Country Link
US (2) US5968822A (de)
EP (5) EP1439226A3 (de)
JP (1) JP4187408B2 (de)
CN (1) CN1272886A (de)
AT (1) ATE318912T1 (de)
AU (1) AU735116B2 (de)
CA (1) CA2296758A1 (de)
DE (1) DE69833667T2 (de)
ES (1) ES2259816T3 (de)
PL (1) PL338949A1 (de)
TR (1) TR200000578T2 (de)
WO (1) WO1999011798A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
US20040213789A1 (en) * 1997-09-02 2004-10-28 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monoclonal antibody and other anti-heparanase antibodies
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
US20020088019A1 (en) * 1997-09-02 2002-07-04 Oron Yacoby-Zeevi Methods of and pharmaceutical compositions for improving implantation of embryos
US20030161823A1 (en) * 1998-08-31 2003-08-28 Neta Ilan Therapeutic and cosmetic uses of heparanases
US6348344B1 (en) * 1997-09-02 2002-02-19 Insight Strategy & Marketing Ltd. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
US6699672B1 (en) * 1997-09-02 2004-03-02 Insight Biopharmaceuticals Ltd. Heparanase specific molecular probes and their use research and medical applications
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
JP2002510462A (ja) * 1997-10-28 2002-04-09 ジ・オーストラリアン・ナショナル・ユニバーシティー 哺乳類のエンドグルクロニダーゼをコードする単離された核酸分子およびその使用
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds
AU2759199A (en) * 1998-02-24 1999-09-15 Pharmacia & Upjohn Company Human platelet heparanase polypeptides, polynucleotide molecules that encode them, and methods for the identification of compounds that alter heparanase activity
US7056504B1 (en) 1998-08-27 2006-06-06 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase I and II
EP1109919A2 (de) * 1998-08-27 2001-06-27 Massachusetts Institute Of Technology Von heparinase i und ii abgeleitete heparinasen
US20020068054A1 (en) * 2000-09-11 2002-06-06 Insight Strategy & Marketing Ltd. And Hadasit Medical Research Services And Development Ltd. Therapeutic and cosmetic uses of heparanases
US20030217375A1 (en) * 1998-08-31 2003-11-20 Eyal Zcharia Transgenic animals expressing heparanase and uses thereof
AU2878600A (en) * 1999-03-01 2000-09-21 Hadasit Medical Research Services & Development Company Ltd Polynucleotide encoding a polypeptide having heparanase activity and expression of same in genetically modified cells
US7412332B1 (en) 1999-04-23 2008-08-12 Massachusetts Institute Of Technology Method for analyzing polysaccharides
US20040224922A1 (en) * 1999-08-26 2004-11-11 Malcolm King Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto
JP2003510053A (ja) * 1999-09-23 2003-03-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング ヘパラナーゼ蛋白質ファミリーの１種、ヘパラナーゼ−２
WO2001046392A2 (en) * 1999-12-22 2001-06-28 Oxford Glycosciences (Uk) Ltd. Homologues of human heparanase and splice variants thereof
WO2001066772A2 (en) * 2000-03-08 2001-09-13 Massachusetts Institute Of Technology Heparinase iii and uses thereof
ATE426805T1 (de) * 2000-09-12 2009-04-15 Massachusetts Inst Technology Verfahren und produkte, die mit niedermolekularem heparin assoziiert sind
EP1356083A2 (de) 2000-09-15 2003-10-29 Reddy US Therapeutics, Inc. Verfahren und zusammensutzungen zur bestimmung von glycosidase
EP1333862A4 (de) * 2000-10-17 2004-08-18 Insight Strategy & Marketing Verfahren und pharmazeutische zusammensetzungen zur verbesserung der implantation von embryos
AU2440802A (en) 2000-10-18 2002-04-29 Massachusetts Inst Technology Methods and products related to pulmonary delivery of polysaccharides
WO2002044353A2 (en) * 2000-11-30 2002-06-06 Sangamo Biosciences, Inc. Human heparanase gene regulatory sequences
FR2818131B1 (fr) * 2000-12-14 2005-02-11 Oreal Composition cosmetique comprenant de l'heparanase
CA2432157A1 (en) * 2000-12-19 2002-06-27 Insight Strategy And Marketing Ltd. The use of ecm degrading enzymes for the improvement of cell transplantation
AU2002243630A1 (en) * 2001-01-23 2002-08-06 Massachusetts Institute Of Technology Solid- and solution -phase synthesis of heparin and other glycosaminoglycans
EP1417304A4 (de) * 2001-07-13 2005-11-23 Imclone Systems Inc Verfahren und zusammensetzung zur hemmung der heparanaseaktivität
US6671189B2 (en) * 2001-11-09 2003-12-30 Minebea Co., Ltd. Power converter having primary and secondary side switches
CH696701A5 (de) 2001-12-18 2007-10-15 Hoffmann La Roche Verfahren zum Testen eines Mittels auf dessen Fähigkeit, die Heparanaseaktivität zu hemmen.
CA2493509C (en) * 2002-06-03 2010-03-09 Massachusetts Institute Of Technology Rationally designed polysaccharide lyases derived from chondroitinase b
EP1522527A1 (de) * 2002-06-21 2005-04-13 Sanden Corporation Vorrichtung zur herstellung von mineralwasser
WO2004043989A2 (en) * 2002-11-07 2004-05-27 Medarex, Inc. Human monoclonal antibodies to heparanase
WO2005014619A2 (en) 2003-03-28 2005-02-17 Thomas Jefferson University Heparin-binding peptides and uses thereof
US20060269552A1 (en) * 2003-06-09 2006-11-30 Oron Yacoby-Zeevi Heparanase activity neutralizing anti-heparanase monclonal antibody and other anti-heparanase antibodies
US20070009989A1 (en) * 2003-09-26 2007-01-11 Christian Steinkuhler Synthetic heparanase molecules and uses thereof
US8093031B2 (en) * 2005-09-20 2012-01-10 Carmel-Haifa University Economic Corp. Ltd. Heparanases and splice variants thereof, polynucleotides encoding them and uses thereof
US20080220429A1 (en) * 2006-10-27 2008-09-11 Tishkoff Sarah A Single nucleotide polymorphisms and the identification of lactose intolerance
RU2576033C2 (ru) * 2009-12-03 2016-02-27 Опко Хелс, Инк. Составы на основе гиперсулфатированных дисахаридов
CA2904236A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Heparanase expression in t lymphocytes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061689A (en) * 1986-12-24 1991-10-29 Bioderm, Inc. Zinc bacitracin containing wound dressing
US5571506A (en) * 1989-08-14 1996-11-05 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aromatic oligomeric compounds useful as mimics of bioactive macromolecules
US5362641A (en) * 1989-08-23 1994-11-08 Hadassah Medical Organization Kiryat Hadassah Heparanase derived from human Sk-Hep-1 cell line
US5300059A (en) * 1991-11-19 1994-04-05 Hydro Slip Technologies Inc. Bloodbag and method of making same
WO1993018745A1 (en) * 1992-03-23 1993-09-30 Geda International S.A. Use of antiviral coating for latex items such as condoms
WO1995004158A1 (en) * 1993-07-29 1995-02-09 The Upjohn Company Use of heparanase to identify and isolate anti-heparanase compound
US5565193A (en) * 1993-08-05 1996-10-15 Procter & Gamble Hair styling compositions containing a silicone grafted polymer and low level of a volatile hydrocarbon solvent
DE69700902T2 (de) * 1996-01-23 2000-07-20 Rapigene, Inc. Verfahren zur erkennung von ligandenpaar bindung mit erhöter empfindlichkeit
US6177545B1 (en) * 1997-09-02 2001-01-23 Insight Strategy & Marketing Ltd. Heparanase specific molecular probes and their use in research and medical applications
US6348344B1 (en) * 1997-09-02 2002-02-19 Insight Strategy & Marketing Ltd. Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same
US5968822A (en) * 1997-09-02 1999-10-19 Pecker; Iris Polynucleotide encoding a polypeptide having heparanase activity and expression of same in transduced cells
JP2002510462A (ja) * 1997-10-28 2002-04-09 ジ・オーストラリアン・ナショナル・ユニバーシティー 哺乳類のエンドグルクロニダーゼをコードする単離された核酸分子およびその使用
GB9802725D0 (en) * 1998-02-09 1998-04-08 Ciba Geigy Ag Organic compounds

Also Published As

Publication number Publication date
EP1676912A3 (de) 2008-12-31
US6664105B1 (en) 2003-12-16
EP0998569A1 (de) 2000-05-10
AU735116B2 (en) 2001-06-28
PL338949A1 (en) 2000-12-04
CN1272886A (zh) 2000-11-08
EP1439226A3 (de) 2004-10-06
TR200000578T2 (tr) 2000-07-21
CA2296758A1 (en) 1999-03-11
EP0998569A4 (de) 2000-08-16
JP2001514855A (ja) 2001-09-18
EP1439193A3 (de) 2004-10-06
EP1489183A1 (de) 2004-12-22
JP4187408B2 (ja) 2008-11-26
EP1439193A2 (de) 2004-07-21
WO1999011798A1 (en) 1999-03-11
EP1439226A2 (de) 2004-07-21
AU9125898A (en) 1999-03-22
EP1489183B1 (de) 2011-10-26
EP1676912A2 (de) 2006-07-05
ES2259816T3 (es) 2006-10-16
EP0998569B1 (de) 2006-03-01
US5968822A (en) 1999-10-19
DE69833667D1 (de) 2006-04-27
DE69833667T2 (de) 2007-03-08
EP1439193B1 (de) 2013-08-28

Similar Documents

Publication Publication Date Title
ATE318912T1 (de) Polynukleotid kodierend für ein polypeptid mit heparanase-aktivität und dessen expression in transduzierten zellen
DK72593D0 (da) Rekombinant protein
DE69535147D1 (de) Überexpression von säugetier- und virusproteinen
ATE145940T1 (de) Dns-sequenzen, die polypeptiden mit beta-1,3- glukanase-aktivität codieren
US6114148C1 (en) High level expression of proteins
DE69732871D1 (de) Basisches Protein Zusammensetzung, basisches Peptid Zusammensetzung und deren Verwendung
HUT73962A (en) New bacillus thuringiensis strains and their insecticidal proteins
DE68920444D1 (de) Kurzfasern und elastomere, verstärkte zusammensetzung mit kurzfasern.
DE69839566D1 (de) Chimäre polypeptide, die das fragment b des shigatoxins sowie peptide von therapeutischem interesse enthalten
DE68908633D1 (de) Polypeptide mit zellenverstreuender Aktivität.
DE69734141D1 (de) PROTEIN, DAS FÜR MENSCHLICHE Th2-ZELLEN SPEZIFISCH IST, DAFÜR KODIERENDES GEN UND KORRESPONDIERENDE TRANSFORMANTE, REKOMBINANTER VEKTOR UND MONOKLONALER ANTKÖRPER
WO1999064587A8 (fr) Polypeptides possedant une activite de type beta-secretase
ATA168590A (de) Für das baumpollenallergen p14 codierende rekombinante dna-moleküle, daraus hergestellte und abgeleitete polypeptide und deren verwendung
ATE321873T1 (de) Rekombinante aav-vektoren für die gentherapie von hämophilie a
DK0394035T3 (da) Gener, der koder for et protein med human MACIF-aktivitet, ekspressionsvektorer indeholdende disse gener, transformantceller og proteiner med human MACIF-aktivitet
DE69735694D1 (de) Polypeptide mit L-Asparaginase Aktivität
DK0745122T3 (da) Galninreceptor, nukleinsyrer, transformerede celler og anvendelser heraf
DE68908138D1 (de) Polypeptide mit zellausdehnungs-aktivitaet.
NO902087L (no) Alfa-amylase-pullulanase-enzym og dna-sekvens som koder for dette, rekombinant dna-molekyl og en rekombinant klon som uttrykker enzymet.
FI840104A7 (fi) Yhdistelmä-DNA-ekspressoimisvektoreita, jotka ovat käyttökelpoisia Bacillus- ja muissa isäntäsoluissa.
DE68918519D1 (de) DNA, welche für ein antikoagulierendes Polypeptid kodiert.
DE69333284D1 (de) Polypeptide mit serotoninerger (5ht5a) rezeptor-aktivität, für sie kodierende nukleinsäuren und ihre verwendung
DE69413515D1 (de) Synthetische Amphipatische Peptide mit antimikrobieller Wirksamkeit
DE69534738D1 (de) Leukocyten-aktivierender Faktor
AR020082A1 (es) Polipeptidos de la proteina c humana, moleculas de adn recombinante que codifican dichos polipeptidos, vectores de transformacion y celulas transformadas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties